Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 19 entries
Sorted by: Best Match Show Resources per page
REM sleep behavior disorder (RBD).

Neurobiology of disease

Hu MT.
PMID: 32599063
Neurobiol Dis. 2020 Sep;143:104996. doi: 10.1016/j.nbd.2020.104996. Epub 2020 Jun 26.

Since its first description in 1986 by Dr. Carlos Schenck, and his group's subsequent report of the delayed emergence of a Parkinsonian disorder in idiopathic RBD patients one decade later, RBD has emerged in recent years as one of...

Cite
Hu MT. REM sleep behavior disorder (RBD). Neurobiol Dis. 2020;143:104996doi: 10.1016/j.nbd.2020.104996.
Hu, M. T. (2020). REM sleep behavior disorder (RBD). Neurobiology of disease, 143104996. https://doi.org/10.1016/j.nbd.2020.104996
Hu, Michele T. "REM sleep behavior disorder (RBD)." Neurobiology of disease vol. 143 (2020): 104996. doi: https://doi.org/10.1016/j.nbd.2020.104996
Hu MT. REM sleep behavior disorder (RBD). Neurobiol Dis. 2020 Sep;143:104996. doi: 10.1016/j.nbd.2020.104996. Epub 2020 Jun 26. PMID: 32599063.
Copy Download .nbib Format: NLM
Cortical Control of Striatal Dopamine Transmission via Striatal Cholinergic Interneurons.

Cerebral cortex (New York, N.Y. : 1991)

Kosillo P, Zhang YF, Threlfell S, Cragg SJ.
PMID: 27566978
Cereb Cortex. 2016 Oct 01;26(11):4160-4169. doi: 10.1093/cercor/bhw252.

Corticostriatal regulation of striatal dopamine (DA) transmission has long been postulated, but ionotropic glutamate receptors have not been localized directly to DA axons. Striatal cholinergic interneurons (ChIs) are emerging as major players in striatal function, and can govern DA...

Cite
Kosillo P, Zhang YF, Threlfell S, et al. Cortical Control of Striatal Dopamine Transmission via Striatal Cholinergic Interneurons. Cereb Cortex. 2016;26(11):4160-4169doi: 10.1093/cercor/bhw252.
Kosillo, P., Zhang, Y. F., Threlfell, S., & Cragg, S. J. (2016). Cortical Control of Striatal Dopamine Transmission via Striatal Cholinergic Interneurons. Cerebral cortex (New York, N.Y. : 1991), 26(11), 4160-4169. https://doi.org/10.1093/cercor/bhw252
Kosillo, Polina, et al. "Cortical Control of Striatal Dopamine Transmission via Striatal Cholinergic Interneurons." Cerebral cortex (New York, N.Y. : 1991) vol. 26,11 (2016): 4160-4169. doi: https://doi.org/10.1093/cercor/bhw252
Kosillo P, Zhang YF, Threlfell S, Cragg SJ. Cortical Control of Striatal Dopamine Transmission via Striatal Cholinergic Interneurons. Cereb Cortex. 2016 Oct 01;26(11):4160-4169. doi: 10.1093/cercor/bhw252. PMID: 27566978; PMCID: PMC5066833.
Copy Download .nbib Format: NLM
Commentary: Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.

Frontiers in neuroscience

Fernandes HJ, Ryan BJ, Wade-Martins R.
PMID: 28066164
Front Neurosci. 2016 Dec 23;10:578. doi: 10.3389/fnins.2016.00578. eCollection 2016.

No abstract available.

Cite
Fernandes HJ, Ryan BJ, Wade-Martins R. Commentary: Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Front Neurosci. 2016;10:578doi: 10.3389/fnins.2016.00578.
Fernandes, H. J., Ryan, B. J., & Wade-Martins, R. (2016). Commentary: Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Frontiers in neuroscience, 10578. https://doi.org/10.3389/fnins.2016.00578
Fernandes, Hugo J R, et al. "Commentary: Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models." Frontiers in neuroscience vol. 10 (2016): 578. doi: https://doi.org/10.3389/fnins.2016.00578
Fernandes HJ, Ryan BJ, Wade-Martins R. Commentary: Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Front Neurosci. 2016 Dec 23;10:578. doi: 10.3389/fnins.2016.00578. eCollection 2016. PMID: 28066164; PMCID: PMC5179548.
Copy Download .nbib Format: NLM
Identification of distinct circulating exosomes in Parkinson's disease.

Annals of clinical and translational neurology

Tomlinson PR, Zheng Y, Fischer R, Heidasch R, Gardiner C, Evetts S, Hu M, Wade-Martins R, Turner MR, Morris J, Talbot K, Kessler BM, Tofaris GK.
PMID: 25909081
Ann Clin Transl Neurol. 2015 Apr;2(4):353-61. doi: 10.1002/acn3.175. Epub 2015 Feb 06.

OBJECTIVE: Whether circulating microvesicles convey bioactive signals in neurodegenerative diseases remains currently unknown. In this study, we investigated the biochemical composition and biological function of exosomes isolated from sera of patients with Parkinson's disease (PD).METHODS: Proteomic analysis was performed...

Cite
Tomlinson PR, Zheng Y, Fischer R, et al. Identification of distinct circulating exosomes in Parkinson's disease. Ann Clin Transl Neurol. 2015;2(4):353-61doi: 10.1002/acn3.175.
Tomlinson, P. R., Zheng, Y., Fischer, R., Heidasch, R., Gardiner, C., Evetts, S., Hu, M., Wade-Martins, R., Turner, M. R., Morris, J., Talbot, K., Kessler, B. M., & Tofaris, G. K. (2015). Identification of distinct circulating exosomes in Parkinson's disease. Annals of clinical and translational neurology, 2(4), 353-61. https://doi.org/10.1002/acn3.175
Tomlinson, Paul R, et al. "Identification of distinct circulating exosomes in Parkinson's disease." Annals of clinical and translational neurology vol. 2,4 (2015): 353-61. doi: https://doi.org/10.1002/acn3.175
Tomlinson PR, Zheng Y, Fischer R, Heidasch R, Gardiner C, Evetts S, Hu M, Wade-Martins R, Turner MR, Morris J, Talbot K, Kessler BM, Tofaris GK. Identification of distinct circulating exosomes in Parkinson's disease. Ann Clin Transl Neurol. 2015 Apr;2(4):353-61. doi: 10.1002/acn3.175. Epub 2015 Feb 06. PMID: 25909081; PMCID: PMC4402081.
Copy Download .nbib Format: NLM
The True Colours Remote Symptom Monitoring System: A Decade of Evolution.

Journal of medical Internet research

Goodday SM, Atkinson L, Goodwin G, Saunders K, South M, Mackay C, Denis M, Hinds C, Attenburrow MJ, Davies J, Welch J, Stevens W, Mansfield K, Suvilehto J, Geddes J.
PMID: 31939746
J Med Internet Res. 2020 Jan 15;22(1):e15188. doi: 10.2196/15188.

The True Colours remote mood monitoring system was developed over a decade ago by researchers, psychiatrists, and software engineers at the University of Oxford to allow patients to report on a range of symptoms via text messages, Web interfaces,...

Cite
Goodday SM, Atkinson L, Goodwin G, et al. The True Colours Remote Symptom Monitoring System: A Decade of Evolution. J Med Internet Res. 2020;22(1):e15188doi: 10.2196/15188.
Goodday, S. M., Atkinson, L., Goodwin, G., Saunders, K., South, M., Mackay, C., Denis, M., Hinds, C., Attenburrow, M. J., Davies, J., Welch, J., Stevens, W., Mansfield, K., Suvilehto, J., & Geddes, J. (2020). The True Colours Remote Symptom Monitoring System: A Decade of Evolution. Journal of medical Internet research, 22(1), e15188. https://doi.org/10.2196/15188
Goodday, Sarah M, et al. "The True Colours Remote Symptom Monitoring System: A Decade of Evolution." Journal of medical Internet research vol. 22,1 (2020): e15188. doi: https://doi.org/10.2196/15188
Goodday SM, Atkinson L, Goodwin G, Saunders K, South M, Mackay C, Denis M, Hinds C, Attenburrow MJ, Davies J, Welch J, Stevens W, Mansfield K, Suvilehto J, Geddes J. The True Colours Remote Symptom Monitoring System: A Decade of Evolution. J Med Internet Res. 2020 Jan 15;22(1):e15188. doi: 10.2196/15188. PMID: 31939746; PMCID: PMC6996723.
Copy Download .nbib Format: NLM
Testing Shortened Versions of Smell Tests to Screen for Hyposmia in Parkinson's Disease.

Movement disorders clinical practice

Auger SD, Kanavou S, Lawton M, Ben-Shlomo Y, Hu MT, Schrag AE, Morris HR, Grosset DG, Noyce AJ.
PMID: 32373655
Mov Disord Clin Pract. 2020 Mar 21;7(4):394-398. doi: 10.1002/mdc3.12928. eCollection 2020 May.

BACKGROUND: Hyposmia is an early feature in neurodegenerative diseases, most notably Parkinson's disease (PD). Using abbreviated smell tests could provide a cost-effective means for large-scale hyposmia screening. It is unclear whether short smell tests can effectively detect hyposmia in...

Cite
Auger SD, Kanavou S, Lawton M, et al. Testing Shortened Versions of Smell Tests to Screen for Hyposmia in Parkinson's Disease. Mov Disord Clin Pract. 2020;7(4):394-398doi: 10.1002/mdc3.12928.
Auger, S. D., Kanavou, S., Lawton, M., Ben-Shlomo, Y., Hu, M. T., Schrag, A. E., Morris, H. R., Grosset, D. G., & Noyce, A. J. (2020). Testing Shortened Versions of Smell Tests to Screen for Hyposmia in Parkinson's Disease. Movement disorders clinical practice, 7(4), 394-398. https://doi.org/10.1002/mdc3.12928
Auger, Stephen D, et al. "Testing Shortened Versions of Smell Tests to Screen for Hyposmia in Parkinson's Disease." Movement disorders clinical practice vol. 7,4 (2020): 394-398. doi: https://doi.org/10.1002/mdc3.12928
Auger SD, Kanavou S, Lawton M, Ben-Shlomo Y, Hu MT, Schrag AE, Morris HR, Grosset DG, Noyce AJ. Testing Shortened Versions of Smell Tests to Screen for Hyposmia in Parkinson's Disease. Mov Disord Clin Pract. 2020 Mar 21;7(4):394-398. doi: 10.1002/mdc3.12928. eCollection 2020 May. PMID: 32373655; PMCID: PMC7197313.
Copy Download .nbib Format: NLM
The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation.

Parkinsonism & related disorders

Lang AE, Stebbins GT, Wang P, Jabbari E, Lamb R, Morris H, Boxer AL.
PMID: 32947108
Parkinsonism Relat Disord. 2020 Oct;79:121-126. doi: 10.1016/j.parkreldis.2020.08.021. Epub 2020 Aug 25.

OBJECTIVE: To develop a patient/care-giver reported scale capable of easily and reliably assessing functional disability in 4 repeat tauopathies (4RTs).BACKGROUND: 4R tauopathies including progressive supranuclear palsy, corticobasal degeneration and a subset of frontotemporal dementias manifest a range of overlapping...

Cite
Lang AE, Stebbins GT, Wang P, et al. The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. Parkinsonism Relat Disord. 2020;79:121-126doi: 10.1016/j.parkreldis.2020.08.021.
Lang, A. E., Stebbins, G. T., Wang, P., Jabbari, E., Lamb, R., Morris, H., Boxer, A. L. (2020). The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. Parkinsonism & related disorders, 79121-126. https://doi.org/10.1016/j.parkreldis.2020.08.021
Lang, Anthony E, et al. "The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation." Parkinsonism & related disorders vol. 79 (2020): 121-126. doi: https://doi.org/10.1016/j.parkreldis.2020.08.021
Lang AE, Stebbins GT, Wang P, Jabbari E, Lamb R, Morris H, Boxer AL. The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. Parkinsonism Relat Disord. 2020 Oct;79:121-126. doi: 10.1016/j.parkreldis.2020.08.021. Epub 2020 Aug 25. PMID: 32947108.
Copy Download .nbib Format: NLM
Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science.

Digital biomarkers

Stephenson D, Alexander R, Aggarwal V, Badawy R, Bain L, Bhatnagar R, Bloem BR, Boroojerdi B, Burton J, Cedarbaum JM, Cosman J, Dexter DT, Dockendorf M, Dorsey ER, Dowling AV, Evers LJW, Fisher K, Frasier M, Garcia-Gancedo L, Goldsack JC, Hill D, Hitchcock J, Hu MT, Lawton MP, Lee SJ, Lindemann M, Marek K, Mehrotra N, Meinders MJ, Minchik M, Oliva L, Romero K, Roussos G, Rubens R, Sadar S, Scheeren J, Sengoku E, Simuni T, Stebbins G, Taylor KI, Yang B, Zach N.
PMID: 33442579
Digit Biomark. 2020 Nov 26;4:28-49. doi: 10.1159/000512500. eCollection 2020.

Innovative tools are urgently needed to accelerate the evaluation and subsequent approval of novel treatments that may slow, halt, or reverse the relentless progression of Parkinson disease (PD). Therapies that intervene early in the disease continuum are a priority...

Cite
Stephenson D, Alexander R, Aggarwal V, et al. Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science. Digit Biomark. 2020;4:28-49doi: 10.1159/000512500.
Stephenson, D., Alexander, R., Aggarwal, V., Badawy, R., Bain, L., Bhatnagar, R., Bloem, B. R., Boroojerdi, B., Burton, J., Cedarbaum, J. M., Cosman, J., Dexter, D. T., Dockendorf, M., Dorsey, E. R., Dowling, A. V., Evers, L. J. W., Fisher, K., Frasier, M., Garcia-Gancedo, L., Goldsack, J. C., Hill, D., Hitchcock, J., Hu, M. T., Lawton, M. P., Lee, S. J., Lindemann, M., Marek, K., Mehrotra, N., Meinders, M. J., Minchik, M., Oliva, L., Romero, K., Roussos, G., Rubens, R., Sadar, S., Scheeren, J., Sengoku, E., Simuni, T., Stebbins, G., Taylor, K. I., Yang, B., & Zach, N. (2020). Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science. Digital biomarkers, 428-49. https://doi.org/10.1159/000512500
Stephenson, Diane, et al. "Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science." Digital biomarkers vol. 4 (2020): 28-49. doi: https://doi.org/10.1159/000512500
Stephenson D, Alexander R, Aggarwal V, Badawy R, Bain L, Bhatnagar R, Bloem BR, Boroojerdi B, Burton J, Cedarbaum JM, Cosman J, Dexter DT, Dockendorf M, Dorsey ER, Dowling AV, Evers LJW, Fisher K, Frasier M, Garcia-Gancedo L, Goldsack JC, Hill D, Hitchcock J, Hu MT, Lawton MP, Lee SJ, Lindemann M, Marek K, Mehrotra N, Meinders MJ, Minchik M, Oliva L, Romero K, Roussos G, Rubens R, Sadar S, Scheeren J, Sengoku E, Simuni T, Stebbins G, Taylor KI, Yang B, Zach N. Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science. Digit Biomark. 2020 Nov 26;4:28-49. doi: 10.1159/000512500. eCollection 2020. PMID: 33442579; PMCID: PMC7768153.
Copy Download .nbib Format: NLM
A Qualitative Study on the Impact of First Steps-A Peer-led Educational Intervention for People Newly Diagnosed with Parkinson's Disease.

Behavioral sciences (Basel, Switzerland)

Soundy A, Collett J, Lawrie S, Coe S, Roberts H, Hu M, Bromley S, Harling P, Reed A, Coeberg J, Carroll C, Dawes H.
PMID: 31658668
Behav Sci (Basel). 2019 Oct 10;9(10). doi: 10.3390/bs9100107.

No abstract available.

Cite
Soundy A, Collett J, Lawrie S, et al. A Qualitative Study on the Impact of First Steps-A Peer-led Educational Intervention for People Newly Diagnosed with Parkinson's Disease. Behav Sci (Basel). 2019;9(10)doi: 10.3390/bs9100107.
Soundy, A., Collett, J., Lawrie, S., Coe, S., Roberts, H., Hu, M., Bromley, S., Harling, P., Reed, A., Coeberg, J., Carroll, C., & Dawes, H. (2019). A Qualitative Study on the Impact of First Steps-A Peer-led Educational Intervention for People Newly Diagnosed with Parkinson's Disease. Behavioral sciences (Basel, Switzerland), 9(10), . https://doi.org/10.3390/bs9100107
Soundy, Andrew, et al. "A Qualitative Study on the Impact of First Steps-A Peer-led Educational Intervention for People Newly Diagnosed with Parkinson's Disease." Behavioral sciences (Basel, Switzerland) vol. 9,10 (2019). doi: https://doi.org/10.3390/bs9100107
Soundy A, Collett J, Lawrie S, Coe S, Roberts H, Hu M, Bromley S, Harling P, Reed A, Coeberg J, Carroll C, Dawes H. A Qualitative Study on the Impact of First Steps-A Peer-led Educational Intervention for People Newly Diagnosed with Parkinson's Disease. Behav Sci (Basel). 2019 Oct 10;9(10). doi: 10.3390/bs9100107. PMID: 31658668; PMCID: PMC6826464.
Copy Download .nbib Format: NLM
Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease.

Frontiers in molecular neuroscience

Fields CR, Bengoa-Vergniory N, Wade-Martins R.
PMID: 31866823
Front Mol Neurosci. 2019 Dec 05;12:299. doi: 10.3389/fnmol.2019.00299. eCollection 2019.

Parkinson's disease (PD) is one of the most common neurodegenerative disorders with a global burden of approximately 6.1 million patients. Alpha-synuclein has been linked to both the sporadic and familial forms of the disease. Moreover, alpha-synuclein is present in...

Cite
Fields CR, Bengoa-Vergniory N, Wade-Martins R. Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease. Front Mol Neurosci. 2019;12:299doi: 10.3389/fnmol.2019.00299.
Fields, C. R., Bengoa-Vergniory, N., & Wade-Martins, R. (2019). Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease. Frontiers in molecular neuroscience, 12299. https://doi.org/10.3389/fnmol.2019.00299
Fields, Carroll Rutherford, et al. "Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease." Frontiers in molecular neuroscience vol. 12 (2019): 299. doi: https://doi.org/10.3389/fnmol.2019.00299
Fields CR, Bengoa-Vergniory N, Wade-Martins R. Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease. Front Mol Neurosci. 2019 Dec 05;12:299. doi: 10.3389/fnmol.2019.00299. eCollection 2019. PMID: 31866823; PMCID: PMC6906193.
Copy Download .nbib Format: NLM
A Ketone Ester Drink Enhances Endurance Exercise Performance in Parkinson's Disease.

Frontiers in neuroscience

Norwitz NG, Dearlove DJ, Lu M, Clarke K, Dawes H, Hu MT.
PMID: 33100965
Front Neurosci. 2020 Sep 30;14:584130. doi: 10.3389/fnins.2020.584130. eCollection 2020.

OBJECTIVES: Routine exercise is thought to be among the only disease-modifying treatments for Parkinson's disease; however, patients' progressive loss of physical ability limits its application. Therefore, we sought to investigate whether a ketone ester drink, which has previously been...

Cite
Norwitz NG, Dearlove DJ, Lu M, et al. A Ketone Ester Drink Enhances Endurance Exercise Performance in Parkinson's Disease. Front Neurosci. 2020;14:584130doi: 10.3389/fnins.2020.584130.
Norwitz, N. G., Dearlove, D. J., Lu, M., Clarke, K., Dawes, H., & Hu, M. T. (2020). A Ketone Ester Drink Enhances Endurance Exercise Performance in Parkinson's Disease. Frontiers in neuroscience, 14584130. https://doi.org/10.3389/fnins.2020.584130
Norwitz, Nicholas G, et al. "A Ketone Ester Drink Enhances Endurance Exercise Performance in Parkinson's Disease." Frontiers in neuroscience vol. 14 (2020): 584130. doi: https://doi.org/10.3389/fnins.2020.584130
Norwitz NG, Dearlove DJ, Lu M, Clarke K, Dawes H, Hu MT. A Ketone Ester Drink Enhances Endurance Exercise Performance in Parkinson's Disease. Front Neurosci. 2020 Sep 30;14:584130. doi: 10.3389/fnins.2020.584130. eCollection 2020. PMID: 33100965; PMCID: PMC7556340.
Copy Download .nbib Format: NLM
[No title available]

Frontiers in cellular neuroscience

Bogetofte H, Jensen P, Ryding M, Schmidt SI, Okarmus J, Ritter L, Worm CS, Hohnholt MC, Azevedo C, Roybon L, Bak LK, Waagepetersen H, Ryan BJ, Wade-Martins R, Larsen MR, Meyer M.
PMID: 31333417
Front Cell Neurosci. 2019 Jul 05;13:297. doi: 10.3389/fncel.2019.00297. eCollection 2019.

The protein parkin, encoded by the

Cite
Bogetofte H, Jensen P, Ryding M, et al. . Front Cell Neurosci. 2019;13:297doi: 10.3389/fncel.2019.00297.
Bogetofte, H., Jensen, P., Ryding, M., Schmidt, S. I., Okarmus, J., Ritter, L., Worm, C. S., Hohnholt, M. C., Azevedo, C., Roybon, L., Bak, L. K., Waagepetersen, H., Ryan, B. J., Wade-Martins, R., Larsen, M. R., & Meyer, M. (2019). . Frontiers in cellular neuroscience, 13297. https://doi.org/10.3389/fncel.2019.00297
Bogetofte, Helle, et al. "." Frontiers in cellular neuroscience vol. 13 (2019): 297. doi: https://doi.org/10.3389/fncel.2019.00297
Bogetofte H, Jensen P, Ryding M, Schmidt SI, Okarmus J, Ritter L, Worm CS, Hohnholt MC, Azevedo C, Roybon L, Bak LK, Waagepetersen H, Ryan BJ, Wade-Martins R, Larsen MR, Meyer M. . Front Cell Neurosci. 2019 Jul 05;13:297. doi: 10.3389/fncel.2019.00297. eCollection 2019. PMID: 31333417; PMCID: PMC6624735.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 19 entries